Literature DB >> 4007033

In vitro--in vivo correlation of dissolution, a time scaling problem? Transformation of in vitro results to the in vivo situation, using theophylline as a practical example.

D Brockmeier, H J Dengler, D Voegele.   

Abstract

Two principal approaches to demonstrating the continuous in vivo relevance of an in vitro dissolution test are outlined. The first uses the convolution technique to predict the concentration-time course in vivo; the second uses deconvolution as a mathematical tool to estimate the in vivo dissolution profile. The weighting function must be known to utilise either technique. Defined by the aim of the analysis the dose-normalized response to the oral solution is regarded as the weighting function (Impulse Response). In both cases the essential step is continuous comparison of the predicted time dependent data with actual readings of the same class. To permit the prediction of concentration-time data from in vitro dissolution data the basic equations for the transformation of the time base from in vitro to in vivo conditions are developed. The transformation is essential, since one cannot assume that the time scales for the in vitro and the in vivo experiment are definitely the same. The estimated in vivo dissolution profile using the deconvolution technique gives a hypothetical image of the true in vivo dissolution curve. Comparison with in vitro dissolution test results, using one of the equivalence testing procedures, reveals how closely and for how long the in vitro dissolution test simulates the in vivo dissolution process. For the formulation of theophylline studied, equivalence of the in vitro and the estimated in vivo dissolution profiles was not confirmed for the entire period of observation, but it was demonstrated for approximately the first 5 h. The later inequivalence is not due to possible non-linear or time-dependent kinetics of theophylline. There is a discussion of whether a change in pH, agitation of the formulation, diffusion conditions or the absorption rate constant along the gastrointestinal tract might explain the biphasic linear correlation of the in vitro and in vivo data observed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4007033     DOI: 10.1007/bf00543326

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  EFFECT OF DOSAGE FORM ON DRUG ABSORPTION A FREQUENT VARIABLE IN CLINICAL PHARMACOLOGY.

Authors:  G LEVY
Journal:  Arch Int Pharmacodyn Ther       Date:  1964-11-01

2.  Motility of the small intestine with non-flocculating medium; a review of 173 roentgen examinations.

Authors:  I E KIRSH
Journal:  Gastroenterology       Date:  1956-09       Impact factor: 22.682

3.  Dose-dependent kinetics of theophylline disposition in asthmatic children.

Authors:  M Weinberger; E Ginchansky
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

4.  Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets.

Authors:  H Bechgaard; K Ladefoged
Journal:  J Pharm Pharmacol       Date:  1978-11       Impact factor: 3.765

5.  [The determination of pharmacokinetic parameters from surveillance protocols of sepsis therapy].

Authors:  H M von Hattingberg; R Roos; D Brockmeier; W Marget
Journal:  Internist (Berl)       Date:  1983-03       Impact factor: 0.743

6.  [In vivo testing of a peroral theophylline depot preparation with zero-order release].

Authors:  B C Lippold; H Förster
Journal:  Arzneimittelforschung       Date:  1984

7.  Numerical deconvolution by least squares: use of prescribed input functions.

Authors:  D J Cutler
Journal:  J Pharmacokinet Biopharm       Date:  1978-06

8.  Measurement of excretion characteristics of theophylline and its major metabolites.

Authors:  J H Jonkman; D Tang; R A Upton; S Riegelman
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Nonlinear theophylline elimination.

Authors:  D D Tang-Liu; R L Williams; S Riegelman
Journal:  Clin Pharmacol Ther       Date:  1982-03       Impact factor: 6.875

10.  Non-linear elimination processes of theophylline.

Authors:  U Gundert-Remy; R Hildebrandt; N Hengen; E Weber
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more
  11 in total

1.  Improving of the accuracy of in vitro-in vivo linear correlation using kinetic models for ultra sustained release theophylline tablets.

Authors:  E Karasulu; S Aktogu; H Y Karasulu; A Aydogdu; I Tuglular; G Ertan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Oct-Dec       Impact factor: 2.441

2.  The relevance of residence time theory to pharmacokinetics.

Authors:  M Weiss
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

3.  A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.

Authors:  Cian Costello; Stefaan Rossenu; An Vermeulen; Adriaan Cleton; Adrian Dunne
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-07-07       Impact factor: 2.745

4.  A novel extravascular input function for the assessment of drug absorption in bioavailability studies.

Authors:  M Weiss
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

5.  A novel beads-based dissolution method for the in vitro evaluation of extended release HPMC matrix tablets and the correlation with the in vivo data.

Authors:  Uroš Klančar; Boštjan Markun; Saša Baumgartner; Igor Legen
Journal:  AAPS J       Date:  2012-11-28       Impact factor: 4.009

6.  Evaluating In Vivo-In Vitro Correlation Using a Bayesian Approach.

Authors:  Junshan Qiu; Marilyn Martinez; Ram Tiwari
Journal:  AAPS J       Date:  2016-02-19       Impact factor: 4.009

7.  Generalizations in linear pharmacokinetics using properties of certain classes of residence time distributions. II. Log-concave concentration-time curves following oral administration.

Authors:  M Weiss
Journal:  J Pharmacokinet Biopharm       Date:  1987-02

8.  Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.

Authors:  J Ostrowski; G Gaul; D Voegele; D Brockmeier; K Resag
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  A system-approach method for the adjustment of time-varying continuous drug infusion in individual patients: a simulation study.

Authors:  Mária Durisová; Ladislav Dedík
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-12       Impact factor: 2.745

10.  Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation.

Authors:  N Katori; N Aoyagi; T Terao
Journal:  Pharm Res       Date:  1995-02       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.